AI Article Synopsis
- Ovarian cancer is the sixth most common cancer in women, with specific treatment involving surgery and chemotherapy, and new drugs like PARP inhibitors emerging for improvement.
- Recent studies on veliparib, a PARP inhibitor, have demonstrated promise for treating BRCA-associated ovarian tumors, with ongoing research investigating its effectiveness in different treatment settings.
- Experts believe more trials, especially phase 3, are necessary to determine the best use of veliparib in ovarian cancer treatment, whether alone, in combination with other therapies, or as maintenance therapy.
Article Abstract
Introduction: Ovarian cancer represents the sixth most commonly diagnosed cancer among women, with an incidence of 6.1 cases per 100.000 women and a cumulative lifetime risk of 0.5%. Treatment is based on debulking surgery and platinum-based chemotherapy, with the potential combination with taxane. However, the recently available data on the genetic basis and aetiology of ovarian cancer has led to the development of new anticancer drugs. Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most promising new classes of targeted agents currently under investigation for the treatment of ovarian cancer. Veliparib is a small molecule that inhibits both PARP-1 and PARP-2 and was originally shown to be efficacious in BRCA-associated tumors.
Areas Covered: This manuscript reviews the Phase I and II studies investigating the use of veliparib in ovarian cancer. This article also provides and discusses the pharmacokinetics and pharmacodynamics of veliparib.
Expert Opinion: It is still being discussed whether PARP inhibitors should be used in a front-line or relapsed setting, alone or in combination with cytotoxic chemotherapy or as maintenance treatment. In terms of veliparib, further investigations are needed to explore its full potential in ovarian cancer. It is hoped that the ongoing phase 3 trials will help to further elucidate it potential as a treatment option.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/13543784.2016.1146677 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of homologous recombination deficiency on the prognosis of epithelial ovarian cancer.
Clin Transl Med
January 2025
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.
Iron oxide nanoparticles: a versatile nanoplatform for the treatment and diagnosis of ovarian cancer.
Ther Deliv
December 2024
Department of Pharmaceutics, University Institute of Pharma Sciences, Chandigarh University, Mohali, India.
Ovarian cancer remains one of the main causes of human mortality, accounting for millions of deaths every year. Despite of several clinical options such as chemotherapy, photodynamic therapy (PDT), hormonal treatment, radiation therapy, and surgery to manage this disease, the mortality rate is still very high. This alarming statistic highlights the urgent need for innovative approaches to improve both diagnosis and treatment.
View Article and Find Full Text PDFBackground: Prior to COVID-19, little was known about how risks associated with such a pandemic would compete with and influence patient decision making regarding cancer risk reducing medical decision making. We investigated how the pandemic affected preferences for medical risk-reducing strategies among women at elevated risk of breast or ovarian cancer.
Methods: We conducted a discrete choice experiment.
Exploring the impact of exercise on women with ovarian cancer: A call for more methodologically standardized RCTs to enable a realistic systematic review.
Eur J Surg Oncol
December 2024
Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Malta.
Introduction: Ovarian cancer remains a leading cause of mortality among gynecological malignancies, often diagnosed at advanced stages due to nonspecific symptoms and limited screening tools. Standard treatment, including cytoreductive surgery and chemotherapy, can cause fatigue, physical dysfunction, and psychological distress, impacting quality of life. Exercise interventions have shown potential to mitigate these effects, but inconsistent methodologies in randomized controlled trials (RCTs) limit reliable conclusions and clinical integration.
View Article and Find Full Text PDFAcute Myocardial and Hemorrhagic Cerebral Infarction Secondary to Non-bacterial Thrombotic Endocarditis in a Patient with Advanced Uterine and Ovarian Cancer.
Intern Med
December 2024
Division of Cardiovascular Surgery, Oita Prefectural Hospital, Japan.
Non-bacterial thrombotic endocarditis (NBTE) causes myocardial and cerebral infarctions and is associated with advanced stages of malignancy. However, only a few cases of myocardial and cerebral infarctions have been reported in the same patient. We herein report a 47-year-old woman with advanced uterine and ovarian cancer who experienced acute myocardial infarction (MI) after receiving chemotherapeutic intervention for the cancer and hemorrhagic cerebral infarction 1 month after admission for acute MI, attributable to NBTE of the aortic valve.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!